The Latest Breaking News from BristolMyers Squibb Company

High inflation and surging interest rates have heightened fears of a global recession. Amid this uncertain macroeconomic environment, it could be wise to scoop up fundamentally strong stocks Bristol-Myers Squibb (BMY), Centene (CNC), and Ryerson Holding (RYI) for solid long-term returns. These stocks have a Strong Buy rating in our…

The Fed launched another 75-basis-point rate hike this week and signaled it would keep increasing rates until inflation is under control. The consecutive rate hikes are raising recession concerns. We think fundamentally solid stocks Bristol-Myers (BMY), AT&T (T), and Gilead Sciences (GILD), which have the potential to deliver steady returns…

The Nasdaq Composite dropped by around 150 points on Thursday. Investors, meanwhile, focused on some notable insider trades.

The stock market has been under pressure amid the high inflation and the Fed’s hawkish tilt. The Fed launched another 75 basis-point rate hike on Wednesday and indicated that it would keep increasing rates to bring down inflation to the target level. Thus, we think fundamentally solid stocks AbbVie (ABBV),…

The rising prevalence of chronic diseases and the aging population are major growth drivers for the healthcare industry. In addition, increased investments in technological advancements should further bolster the industry’s growth. Thus, we think it may be prudent to buy quality healthcare stocks Pfizer Inc. (PFE), Merck & Co. (MRK),…

Persistent rate hikes by the Fed and rising odds of a recession have aggravated market turbulence and led investors to seek refuge in defensive sectors such as healthcare. Defensive stocks tend to perform well in declining markets due to the steady demand for their products. Hence, consistent dividend-yielding drug stocks…

Rising prevalence of chronic diseases and the increasing aging population are significant growth drivers of the healthcare industry. Moreover, growing investments in technological advancements should bode well for the industry. Thus, we think investing in quality healthcare stocks Johnson & Johnson (JNJ), Pfizer (PFE), Novo Nordisk (NVO), Bristol-Myers Squibb (BMY),…

Recession odds are rising due to the onslaught of aggressive rate hikes by the Fed. Healthcare is conventionally considered a defensive sector. Hence, we think Johnson & Johnson (JNJ), AbbVie (ABBV), and Bristol-Myers Squibb (BMY) might be solid buys now. Read on….

The U.S. market came back in July and early August owing to a robust job market, strong corporate earnings, and a slight decline in inflation. However, the Fed’s hawkish stance to hike the interest rates aggressively until inflation comes down to the target level is expected to keep the market…

Substantial investments in R&D, an aging population, and growing demand for advanced drugs to treat chronic diseases should drive the pharmaceutical industry’s growth. Therefore, investing in fundamentally strong and dividend-paying pharma stocks Johnson & Johnson (JNJ) and Bristol-Myers Squibb (BMY) could help dodge the current market volatility and generate substantial…

The S&P 500 is coming off its four-week win streak amid signals of cooling price increases. However, inflation is still running hot near a 40-year high, which might induce the Fed to continue its policy rate hikes. We think income stocks AbbVie (ABBV), Amgen (AMGN), Pfizer (PFE), Bristol-Myers Squibb (BMY),…